Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream

• Hlavní autoři: Michael D. Howell (Autor), Fiona I. Kuo (Autor), Beth Rumberger (Autor), Erika Boarder (Autor), Kang Sun (Autor), Kathleen Butler (Autor), John E. Harris (Autor), Pearl Grimes (Autor), David Rosmarin (Autor)
• Médium: Kniha
• Vydáno: Elsevier, 2023-11-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Background: Efficacy of ruxolitinib cream, a topical Jak1/Jak2 inhibitor, was demonstrated in a phase 2 trial in patients with vitiligo. Objective: This study aimed to characterize circulating inflammatory biomarker profiles in patients who demonstrated ≥50% improvement in facial Vitiligo Area Scori...